CN114831958A - Flunixin meglumine particles and preparation method thereof - Google Patents
Flunixin meglumine particles and preparation method thereof Download PDFInfo
- Publication number
- CN114831958A CN114831958A CN202210513461.3A CN202210513461A CN114831958A CN 114831958 A CN114831958 A CN 114831958A CN 202210513461 A CN202210513461 A CN 202210513461A CN 114831958 A CN114831958 A CN 114831958A
- Authority
- CN
- China
- Prior art keywords
- flunixin meglumine
- particles
- mixture
- prepared
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention provides flunixin meglumine particles and a preparation method thereof, wherein the flunixin meglumine particles comprise the following components in parts by weight: 2.50-20.00 parts of flunixin meglumine, 80.00-97.50 parts of available drug carriers, 0.10-5.00 parts of flavoring agents, 0.10-5.00 parts of adhesives and 0.10-5.00 parts of enteric coating agents, wherein the preparation method of the flunixin meglumine particles comprises the following steps: (1) mixing flunixin meglumine, available medicinal carrier and correctant uniformly to obtain semi-finished product; (2) and adding an adhesive into the semi-finished product prepared by the S1 to prepare particles of 30-60 meshes. The flunixin meglumine is mixed with the available drug carrier and the flavoring agent, the mixture is prepared into particles with a certain particle size by using the adhesive, and then the particles are prepared into enteric-coated particles in a fluidized bed by using the enteric coating agent, so that the problem of palatability is solved, and a novel process preparation method is provided for the preparation of the flunixin meglumine particles.
Description
Technical Field
The invention relates to the technical field of medicines, and particularly relates to flunixin meglumine particles and a preparation method thereof.
Background
Flunixin meglumine belongs to veterinary anti-inflammatory and analgesic drugs. Flunixin meglumine has the effects of relieving fever, diminishing inflammation and easing pain, can obviously improve clinical symptoms when being used alone or in combination with antibiotics, and can enhance the activity of the antibiotics. Veterinary medicine is commonly used for relieving the pain caused by the visceral colic and the muscular and skeletal disorder of horses and resisting inflammation; the composition can be used for controlling acute inflammation caused by infection of various diseases of cattle, such as laminitis, arthritis, etc., and can also be used for adjuvant treatment of sow mastitis, metritis and agalactia syndrome. The flunixin meglumine can be prepared into common dosage forms such as injection, tablets and granules.
However, flunixin meglumine has the disadvantages of large irritation and palatability, in the prior art, the publication No. CN105232486A discloses a flunixin meglumine taste-masking oral disintegrating agent and a preparation method thereof, the preparation is prepared by mixing raw materials of flunixin meglumine and taste masking agent according to the weight ratio of 1: 2-4, carrying out taste masking treatment to prepare a taste-masking solid dispersion, and then uniformly mixing the taste-masking solid dispersion with auxiliary materials including water-soluble filler, disintegrating agent, flavoring agent, lubricant and the like, the flunixin meglumine taste-masking oral disintegrating agent adopts a hot melt extrusion technology to achieve the taste masking effect, the medicament is disintegrated in the oral cavity, and the taste masking effect is difficult to ensure; the publication No. CN104257614 discloses a flunixin meglumine coated particle and a preparation method thereof, and discloses a flunixin meglumine coated particle which is prepared by firstly dissolving raw materials in a solvent (used as an adhesive), then spraying the raw materials into auxiliary materials which are uniformly mixed in a fluidized bed for granulation, and finally spraying water-soluble coating liquid, wherein the same product is dissolved in the oral cavity.
Disclosure of Invention
In order to solve the defects of the prior art, the flunixin meglumine particles and the preparation method thereof are provided.
A flunixin meglumine granule comprises the following components in parts by weight:
preferably, the usable pharmaceutical carrier is one or a mixture of more of glucose, lactose, starch and sugar alcohol.
Preferably, the flavoring agent is one or a mixture of more of sucralose, aspartame, vanillin and sucrose.
Preferably, the adhesive is one or a mixture of more of sodium carboxymethylcellulose, methylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, sodium alginate, starch and PVP.
Preferably, the enteric coating agent is one or a mixture of more of shellac, cellulose acetate phthalate, seaweed gel, polyvinyl alcohol acetate phthalate, acrylic resin and hydroxypropyl methyl cellulose titanate.
A preparation method of flunixin meglumine particles comprises the following steps:
s1, uniformly mixing flunixin meglumine, an available medicine carrier and a flavoring agent to prepare a semi-finished product;
s2, adding an adhesive into the semi-finished product prepared by the S1 to prepare particles of 30-60 meshes;
s3, dissolving the enteric coating agent into a coating solution by using a solvent, spraying the coating solution on the granules prepared in the step (2) in a fluidized bed to carry out coating, and preparing the flunixin meglumine granules, wherein the solvent is one or a mixture of water, ethanol, acetone and ethyl acetate.
Has the advantages that:
(1) the flunixin meglumine granules are prepared by mixing flunixin meglumine with a pharmaceutically acceptable carrier and a flavoring agent, preparing granules with a certain particle size by using an adhesive, and preparing enteric-coated granules in a fluidized bed by using an enteric coating agent.
(2) The invention provides flunixin meglumine particles and a preparation method thereof, which have simple process and strong operability and are suitable for industrial large-scale production.
Detailed Description
For the purpose of enhancing understanding of the present invention, the present invention will be further described in detail with reference to the following examples, which are provided for illustration only and are not to be construed as limiting the scope of the present invention.
The first embodiment is as follows:
the flunixin meglumine particles are prepared from the following components in parts by weight:
the flunixin meglumine granules are prepared by the following method:
(1) uniformly mixing flunixin meglumine, glucose and sucralose to prepare a semi-finished product;
(2) adding the semi-finished product in the step (1) into sodium carboxymethyl cellulose to prepare 20-mesh granules;
(3) dissolving phthalic acid cellulose acetate with acetone to obtain 4.0% coating solution, and spraying the coating solution onto the granules prepared in step (2) in fluidized bed to coat, and making into flunixin meglumine granules.
Example two:
the flunixin meglumine particles are prepared from the following components in parts by weight:
the flunixin meglumine granules are prepared by the following method:
(1) uniformly mixing flunixin meglumine, glucose and aspartame to prepare a semi-finished product;
(2) adding the semi-finished product in the step (1) into sodium carboxymethyl cellulose to prepare 20-mesh granules;
(3) dissolving phthalic acid cellulose acetate with acetone to obtain 4.0% coating solution, and spraying the coating solution onto the granules prepared in step (2) in fluidized bed to coat, and making into flunixin meglumine granules.
Example three:
the flunixin meglumine particles are prepared from the following components in parts by weight:
the flunixin meglumine granules are prepared by the following method:
(1) uniformly mixing flunixin meglumine, glucose and aspartame to prepare a semi-finished product;
(2) adding the semi-finished product in the step (1) into sodium carboxymethyl cellulose to prepare granules of 60 meshes;
(3) dissolving cellulose acetate phthalate in acetone to obtain 10.0% coating solution, and spraying the coating solution onto the granules prepared in step (2) in a fluidized bed to coat, thereby preparing the flunixin meglumine granules.
Example four:
the flunixin meglumine particles are prepared from the following components in parts by weight:
the flunixin meglumine granules are prepared by the following method:
(1) uniformly mixing flunixin meglumine, glucose and aspartame to prepare a semi-finished product;
(2) adding hydroxypropyl methylcellulose and sodium carboxymethylcellulose into the semi-finished product in the step (1) to prepare 80-mesh granules;
(3) dissolving cellulose acetate phthalate in acetone to obtain 5.0% coating solution, and spraying the coating solution onto the granules prepared in step (2) in a fluidized bed to coat, thereby preparing the flunixin meglumine granules.
Example five:
the flunixin meglumine particles are prepared from the following components in parts by weight:
the flunixin meglumine granules are prepared by the following method:
(1) mixing flunixin meglumine, available glucose, sucralose and aspartame uniformly;
(2) adding sodium carboxymethylcellulose into the mixed medicinal powder obtained in the step (1) to prepare granules of 30 meshes;
(3) dissolving cellulose acetate phthalate in acetone to obtain 5.0% coating solution, and spraying the coating solution onto the granules prepared in step (2) in a fluidized bed to coat, thereby preparing the flunixin meglumine granules.
As a further improvement, the above-mentioned is only a preferred embodiment of the present invention, and is not intended to limit the present invention, and any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (6)
1. The flunixin meglumine particles are characterized by comprising the following components in parts by weight:
2. the flunixin meglumine particles as claimed in claim 1, wherein the available pharmaceutical carrier is one or a mixture of glucose, lactose, starch and sugar alcohol.
3. The flunixin meglumine particles of claim 1, wherein the flavoring agent is one or a mixture of sucralose, aspartame, vanillin and sucrose.
4. The flunixin meglumine particles as claimed in claim 1, wherein the binder is one or a mixture of several of sodium carboxymethylcellulose, methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, sodium alginate, starch and PVP.
5. The flunixin meglumine particles of claim 1, wherein the enteric coating agent is one or a mixture of more of shellac, cellulose acetate phthalate, seaweed gel, polyvinyl alcohol acetate phthalate, acrylic resin and hydroxypropylmethyl cellulose titanate.
6. A process for the preparation of flunixin meglumine particles as claimed in any one of claims 1 to 5, comprising the steps of:
s1, uniformly mixing flunixin meglumine, an available medicine carrier and a flavoring agent to prepare a semi-finished product;
s2, adding an adhesive into the semi-finished product prepared by the S1 to prepare particles of 30-60 meshes;
s3, dissolving the enteric coating agent into a coating solution by using a solvent, spraying the coating solution on the granules prepared in the step (2) in a fluidized bed to carry out coating, and preparing the flunixin meglumine granules, wherein the solvent is one or a mixture of water, ethanol, acetone and ethyl acetate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210513461.3A CN114831958A (en) | 2022-05-12 | 2022-05-12 | Flunixin meglumine particles and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210513461.3A CN114831958A (en) | 2022-05-12 | 2022-05-12 | Flunixin meglumine particles and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114831958A true CN114831958A (en) | 2022-08-02 |
Family
ID=82569195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210513461.3A Pending CN114831958A (en) | 2022-05-12 | 2022-05-12 | Flunixin meglumine particles and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114831958A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004161653A (en) * | 2002-11-12 | 2004-06-10 | Dainippon Pharmaceut Co Ltd | Multiple unit type sustained-release preparation |
| CN104257614A (en) * | 2014-09-26 | 2015-01-07 | 郑州福源动物药业有限公司 | Flunixin meglumine coated granule and preparation method thereof |
| CN109106694A (en) * | 2018-08-27 | 2019-01-01 | 佛山市正典生物技术有限公司 | A kind of flunixin meglumine microcapsule formulation and preparation method thereof |
| CN111990674A (en) * | 2020-01-14 | 2020-11-27 | 青岛圣邦健康食品有限公司 | Enteric coating material, preparation method thereof and enteric product |
-
2022
- 2022-05-12 CN CN202210513461.3A patent/CN114831958A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004161653A (en) * | 2002-11-12 | 2004-06-10 | Dainippon Pharmaceut Co Ltd | Multiple unit type sustained-release preparation |
| CN104257614A (en) * | 2014-09-26 | 2015-01-07 | 郑州福源动物药业有限公司 | Flunixin meglumine coated granule and preparation method thereof |
| CN109106694A (en) * | 2018-08-27 | 2019-01-01 | 佛山市正典生物技术有限公司 | A kind of flunixin meglumine microcapsule formulation and preparation method thereof |
| CN111990674A (en) * | 2020-01-14 | 2020-11-27 | 青岛圣邦健康食品有限公司 | Enteric coating material, preparation method thereof and enteric product |
Non-Patent Citations (1)
| Title |
|---|
| 杜德才: ""肠溶包衣材料在药物制剂中的应用"" * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1976489B1 (en) | Multiple unit type sustained release oral formulation comprising zaltoprofen and process for the preparation thereof | |
| WO2013040873A1 (en) | Sustained and controlled release of micro-granule formulation for treating intestinal disease and preparation method thereof | |
| BG64114B1 (en) | Granulate for the preparation of quick decomposition and quick dissolving compositions having high medicamentous form content | |
| CN108066319B (en) | Tofacitinib citrate enteric sustained-release pellet and preparation method thereof | |
| CA1276560C (en) | Process for producing a sustained release ibuprofen preparation | |
| CN1994285B (en) | Sustained release micro-pellet of guaifenesin and preparation process thereof | |
| CN107375247B (en) | Tilmicosin film-controlled enteric sustained-release preparation and preparation method thereof | |
| CN105769773B (en) | Loxoprofen sodium sustained-release pellet | |
| CN109646417B (en) | Trimetazidine sustained release tablet and preparation method thereof | |
| CN114831958A (en) | Flunixin meglumine particles and preparation method thereof | |
| CN101947209B (en) | Divalproex sodium pellets and preparation method thereof | |
| CN101015533A (en) | Sustained release preparation of norfloxacin | |
| CN112494460B (en) | Tilmicosin powder and preparation method thereof | |
| CN113041231B (en) | Tibipenem pivoxil fine granule composition and preparation method thereof | |
| CN113908153A (en) | Buvalracetam pharmaceutical composition, preparation method and application thereof | |
| CN110893179A (en) | Aspirin sustained-release capsule and preparation method thereof | |
| CN112587493A (en) | Oral sustained-release preparation of diclofenac sodium and preparation method thereof | |
| CN104644565A (en) | Doxycycline hydrochloride drug-containing small pills and preparation method thereof | |
| CN111450069A (en) | Metformin hydrochloride oral sustained-release tablet and preparation method thereof | |
| CN114432257B (en) | Bluprofen sustained-release tablet and preparation method thereof | |
| CN101693019A (en) | Doxycycline hydrochloride oral disintegrating tablet for domestic fowls and preparation method thereof | |
| CN109985019B (en) | Controlled-release tilmicosin enteric microcapsule and preparation method thereof | |
| CN100391454C (en) | Preparation of hydrobromic acid dextro methaphen and beta cyclodeatrin compounding object | |
| CN112076174B (en) | Rimantadine hydrochloride tablet and preparation method thereof | |
| CN102552199A (en) | Bulleyaconitine a controlled release tablet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |